Phase 1 and dose-finding study of patritumab (U3-1287), a human monoclonal antibody targeting HER3, in Japanese patients with advanced solid tumors

Cancer Chemotherapy and Pharmacology

Volumn 73, Issue 3, 2014, Pages 511-516

  Wakui, Hiroshi ^a   Yamamoto, Noboru ^a   Nakamichi, Shinji ^a   Tamura, Yousuke ^a   Nokihara, Hiroshi ^a   Yamada, Yasuhide ^a   Tamura, Tomohide ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

HER3; Patritumab; Phase 1 study; Solid tumor; U3 1287

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; DRUG ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR 3; PATRITUMAB; TUMOR MARKER; U 3 1287; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; ASCITES; BACTERIAL PNEUMONIA; BLOOD LEVEL; BREAST CANCER; CANCER PATIENT; CHEILITIS; CLINICAL ARTICLE; CLINICAL STUDY; COLORECTAL CANCER; DIARRHEA; DISEASE COURSE; DOSE CALCULATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELECTROLYTE DISTURBANCE; ESOPHAGUS CANCER; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HUMAN TISSUE; HYPERTRANSAMINASEMIA; INTERSTITIAL LUNG DISEASE; JAPANESE; LUNG NON SMALL CELL CANCER; LYMPHOCYTOPENIA; MACULOPAPULAR RASH; MALE; MAXIMUM PLASMA CONCENTRATION; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; NATIONAL HEALTH ORGANIZATION; NEUTROPENIA; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SARCOMA; SOLID TUMOR; STOMATITIS; THROMBOCYTOPENIA; TREATMENT RESPONSE; UTERINE CERVIX CANCER; VOMITING;

AGED; ANTIBODIES, MONOCLONAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; JAPAN; MALE; MIDDLE AGED; NEOPLASMS; RECEPTOR, ERBB-3; TREATMENT OUTCOME;

EID: 84896035233     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-014-2375-2     Document Type: Article

References (23)

1. Normanno N, Bianco C, De Luca A, Maiello MR, Salomon DS (2003) Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment. Endocr Relat Cancer 10:1-21 (Pubitemid 36457237)
2. Campbell MR, Amin D, Moasser MM (2010) HER3 comes of age: new insights into its functions and role in signaling, tumor biology, and cancer therapy. Clin Cancer Res 16:1373-1383
3. Gullick WJ (1996) The c-erbB3/HER3 receptor in human cancer. Cancer Surv 27:339-349
4. Olayioye MA, Neve RM, Lane HA, Hynes NE (2000) The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 19:3159-3167 (Pubitemid 30428195)
5. Yarden Y, Sliwkowski MX (2001) Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2:127-137 (Pubitemid 33674041)
6. Pinkas-Kramarski R, Soussan L, Waterman H et al (1996) Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. EMBO J 15:2452-2467 (Pubitemid 26151185)
7. Müller-Tidow C, Diederichs S, Bulk E et al (2005) Identification of metastasis associated receptor tyrosine kinases in non-small cell lung cancer. Cancer Res 65:1778-1782 (Pubitemid 40478604)
8. Bièche I, Onody P, Tozlu S, Driouch K, Vidaud M, Lidereau R (2003) Prognostic value of ERBB family mRNA expression in breast carcinomas. Int J Cancer 106:758-765 (Pubitemid 36993401)
9. Yi ES, Harclerode D, Gondo M et al (1997) High c-erbB-3 protein expression is associated with shorter survival in advanced non-small cell lung carcinomas. Mod Pathol 10:142-148 (Pubitemid 27110039)
10. Tanner B, Hasenclever D, Stern K et al (2006) ErbB-3 predicts survival in ovarian cancer. J Clin Oncol 24:4317-4323 (Pubitemid 46630790)
11. Beji A, Horst D, Engel J, Kirchner T, Ullrich A (2012) Toward the prognostic significance and therapeutic potential of HER3 receptor tyrosine kinase in human colon cancer. Clin Cancer Res 18:956-968
12. Xia W, Gerard CM, Liu L et al (2005) Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells. Oncogene 24:6213-6221 (Pubitemid 43080044)
13. Sergina NV, Rausch M, Wang D et al (2007) Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature 445:437-441 (Pubitemid 46160912)
14. Jain A, Penuel E, Mink S, Schmidt J et al (2010) HER kinase axis receptor dimer partner switching occurs in response to EGFR tyrosine kinase inhibition despite failure to block cellular proliferation. Cancer Res 70:1989-1999
15. Wang S, Huang X, Lee C-K, Liu B (2010) Elevated expression of erbB3 confers paclitaxel resistance in erbB2-overexpressing breast cancer cells via upregulation of Survivin. Oncogene 29:4225-4236
16. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y et al (2007) MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316:1039-1043 (Pubitemid 46799492)
17. Treder M, Hartmann S, Ogbagabriel S, Borges E et al (2008) Fully human anti-HER3 monoclonal antibodies (mAbs) inhibit oncogenic signaling and tumor cell growth in vitro and in vivo. In: 99th AACR annual meeting (meeting abstract): LB-20, San Diego, CA
18. Freeman D, Ogbagabriel S, Rothe M, Radinsky R, Treder M (2008) Fully human anti-HER3 monoclonal antibodies (mAbs) have unique in vitro and in vivo functional and antitumor activities versus other HER family inhibitors. In: 99th AACR annual meeting (meeting abstract): LB-21, San Diego, CA
19. Treder M, Ogbagabriel S, Moor R, Schulze-Horsel U, Hettmann T, Rothe M et al (2008) Fully human anti-HER3 mAb U3-1287 (AMG 888) demonstrates unique in vitro and in vivo activities versus other HER family inhibitors in NSCLC models. Eur J Cancer 6(suppl):99(abstract 309)
20. Freeman DJ, Ogbagabriel S, Bready J, Sun J-R, Radinsky R, Hettmann T (2011) U3-1287 (AMG 888), a fully human anti-HER3 mAb, demonstrates in vitro and in vivo efficacy in the FaDu model of human squamous cell carcinoma of the head and neck (SCCHN). Mol Cancer Ther 10(suppl 1):(abstract A182)
21. LoRusso P, Jänne PA, Oliveira M et al (2013) Phase I Study of U3-1287, a Fully Human Anti-HER3 Monoclonal Antibody, in Patients with Advanced Solid Tumors. Clin Cancer Res 19:3078-3087
22. Carney WP, Neumann R, Lipton A et al (2003) Potential clinical utility of serum HER-2/neu oncoprotein concentrations in patients with breast cancer. Clin Chem 49:1579-1598 (Pubitemid 37194212)
23. Lennon S, Barton C, Banken L et al (2009) Utility of serum HER2 extracellular domain assessment in clinical decision making: pooled analysis of 4 trials of trastuzumab in metastatic breast cancer. J Clin Oncol 27:1685-1693